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Abstract
Background: Accrual to oncology clinical trials remains a challenge, particularly during the COVID-19 pandemic. For late
phase clinical trials funded by the National Cancer Institute, the development of these research protocols is a resource-intensive
process; however, mechanisms to optimize patient accrual after trial activation are underdeveloped across the National Clinical
Trial Network (NCTN). Low patient accrual can lead to the premature closure of clinical trials and can ultimately delay the
availability of new, potentially life-saving therapies in oncology.
Objective: The purpose of this study is to formally create an easily implemented tool kit of resources for investigators of
oncology clinical trials within the NCTN, specifically the NRG Oncology cooperative group, in order to optimize patient accrual.
Methods: NRG Oncology sought to formally develop a tool kit of resources to use at specific time points during the lifetime
of NRG Oncology clinical trials. The tools are clearly described and involve the facilitation of engagement of the study principal
investigator with the scientific and patient advocate community during the planning, activation, and accrual periods. Social media
tools are also leveraged to enhance such engagement. The principal investigator (PI) tool kit was created in 2019 and thereafter
piloted with the NRG Oncology/Alliance NRG-LU005 phase II or III trial in small-cell lung cancer. The PI tool kit was developed
by the NRG Oncology Protocol Operations Management committee and was tested with the NRG/Alliance LU005 randomized
trial within the NCTN.
Results: NRG Oncology/Alliance NRG-LU005 has seen robust enrollment, currently 127% of the projected accrual. Importantly,
many of the tool kit elements are already being used in ongoing NRG Oncology trials, with 56% of active NRG trials using at
least one element of the PI tool kit and all in-development trials offered the resource. This underscores the feasibility and potential
benefits of deploying the PI tool kit across all NRG Oncology trials moving forward.
Conclusions: While clinical trial accrual can be challenging, the PI tool kit has been shown to augment accrual in a low-cost
and easily implementable fashion. It could be widely and consistently deployed across the NCTN to improve accrual in oncology
clinical trials.
Trial Registration: ClinicalTrials.gov NCT03811002; https://clinicaltrials.gov/ct2/show/NCT03811002
https://cancer.jmir.org/2022/3/e38514
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Introduction
Approximately 2% of all patients with cancer participate in a
clinical trial in the United States [1]. The reason behind this
seemingly low number is complex and multifactorial [2]—likely
a combination of clinical trials with overly restrictive inclusion
criteria, lack of access to clinical trials in some environments,
low health literacy around clinical trials, and perhaps a
generalized feeling of wanting to move forward with standard
cancer-directed therapies.
In lung cancer, recent clinical trials have led to an explosion in
US Food and Drug Administration approvals of new therapeutic
agents in the last several years, including immunotherapies and
targeted therapies. The American Cancer Society recently
reported the highest percentage drop in cancer mortality, which
was felt to be primarily related to improvements in lung cancer
therapies [3]. Recent data also show that overall survival for
non–small-cell lung cancer has significantly improved, which
is in close correlation with the approval of new targeted
therapies [4]. Taken together, these advances would not have
been possible without the patients who enrolled in clinical trials
investigating these therapies. However, there are significant
barriers to patient recruitment and retention in oncology clinical
trials, including restrictive eligibility criteria, financial barriers,
logistical concerns, and uncertainty around experimental
treatment arms that can make it difficult for patients to enroll
[5,6]. Slow patient accrual to clinical trials ultimately impairs
development of new therapies for patients.
The National Cancer Institute (NCI) National Clinical Trials
Network (NCTN) is composed of 5 cooperative groups, which
are as follows: The Alliance for Clinical Trials in Oncology,
Children’s Oncology Group, The Eastern Cooperative Oncology
Group-American College of Radiology Imaging Network
(ECOG-ACRIN) cancer research group, NRG Oncology, and
Southwest Oncology Group. It develops and conducts federally
funded cancer trials across the United States and Canada [7,8].
Recent data evaluating the association of NCTN trials with
guideline-based care and new drug indications found that nearly
half of all phase-III Southwest Oncology Group trials were
practice influential, meaning they either established the role of
new cancer therapies or confirmed the benefits of standard of
care therapies [9]. NCTN trials are critical to advancing cancer
care, but many trials take years to complete accrual owing to
lower-than-projected accrual rates.
To facilitate the goal of meeting projected clinical trial accrual,
the NRG Oncology Protocol Operations Management (POM)
Committee sought to develop, with input from the NRG
Communications Committee, a tool kit for study principal
investigators of newly activated NRG Oncology trials.
Membership of these committees include physician leaders
across various types of cancers who design and enroll patients
https://cancer.jmir.org/2022/3/e38514
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on clinical trials. The physician membership includes a diverse
array of people who practice in academia, the private sector, as
well as underserved communities. Members also include patient
advocates, statisticians, and administrative leaders with expertise
in clinical trial design. The principal investigator (PI) tool kit
was therefore developed with input from a wide array of
stakeholders involved in clinical trial design, including patients
themselves.
The goal of the PI tool kit is to harness communication-driven
tools to message information about the trial stakeholders
including patients, physicians, health care teams, advocacy
groups, and oncology organizations. The tool kit works to create
a patient-driven message, with a clinical trial patient advocate
working with the principal investigator to cultivate a message
that resonates with the patient community. This builds upon the
concept of patient-centric clinical trials that involve patient
input throughout the life cycle of the clinical trial [10]. Here,
we describe the components of the PI tool kit, and present
18-month accrual data of the first NRG Oncology clinical trial
to incorporate the PI tool kit: NRG/Alliance NRG-LU005
(registered with Clinical Trials.gov: NCT03811002).
Importantly, the PI investigator tool kit is a newly created tool
for clinical trial accrual, and this manuscript details a first pilot
experience using the tool kit. Further studies using
implementation science to integrate the PI tool kit into additional
clinical trials are ongoing, albeit beyond the scope of this
manuscript.

Methods
Tool Kit Development
In January 2019, NRG Oncology POM committee members,
with input from the NRG Communications Committee, began
developing the PI tool kit. It was developed based upon the
cataloguing of best practices and was designed to be formulaic
and easily broken down into discrete tasks to be performed at
designated time points throughout the life cycle of the clinical
trial. The tool kit tasks would be implemented by the overall
study principal investigator with support from NRG Oncology
operations staff. The study principal investigator is defined as
the individual who has led the development of the clinical trial
and who is responsible for the overall conduct of the clinical
trial. The tool kit would use various awareness resources,
communication tools, social media platforms (including
Twitter), general oncology and disease-specific conferences,
patient engagement websites, and disease-specific patient
advocates. Patient advocates would partner with the study
principal investigator to promote patient-centric messaging
about the clinical trial and would be identified through the NRG
Oncology patient advocacy committee.
The PI tool kit components as well as activation time points are
detailed below. Of note, the PI tool kit focuses on methods to
JMIR Cancer 2022 | vol. 8 | iss. 3 | e38514 | p. 2
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enhance patient recruitment and does not specifically address
retention in clinical trials. Patient recruitment refers to the
number of patients registered to participate in a clinical trial.
The terms recruitment and accrual are used interchangeably.
The PI tool kit is shown in Multimedia Appendix 1 and in the
tables below.

Ethical Considerations
The PI tool kit uses social media and scientific communications
tools to enhance clinical trial accrual. The principal investigator
tool kit was piloted using the clinical trial NRG
Oncology/Alliance LU005, which is an approved clinical trial
through the National Cancer Institute’s central institutional
review board (CIRB; IRB00000781).

Tools Used at Trial Activation
In the weeks to months leading up to study activation, a
trial-specific Power Point slide deck is created that provides a
succinct overview of the study, including the study rationale,
patient population and inclusion or exclusion criteria, study
schema, primary and secondary end points, expected accrual,
and projected study length (Table 1). This is created by the
protocol development team in the Operations and Statistics and
Data Management Center offices, in collaboration with the study
principal investigator. Upon completion and approval, it
becomes available under “study documents” tab on the NCI’s
Clinical Trials Support Unit (CTSU) website. A patient brochure
is created for study sites to use as an educational tool for the
trial. For select trials where resources are available, a study
landing page is created on the NRG Oncology website for

patients to easily engage with and obtain more information
about the clinical trial and to identify possible involvement. The
patient landing page and patient brochure development are
assisted by the Communications Committee members. The
patient landing website and brochure require CIRB approval
and are available at both the NRG Oncology website and the
CTSU protocol web page.
Upon study activation, an email communication is sent by the
study principal investigators to the institutional NRG Oncology
contact principal investigators (as well as to the institutional
principal investigators for the study in question) to communicate
that the new trial is activating and any specific information that
may be of value to site principal investigators. The
CIRB-approved patient brochure can also be sent with this
email. The study principal investigator would also create a short
30- to 60-second video aimed at a patient audience, which
describes the study patient population, study rationale, and study
schema. This brief video script includes CIRB approval with
the video initially shared on social media platforms such as
Twitter by both the trial study principal investigator and NRG
Oncology. Patient advocates are also encouraged to help develop
this video to ensure the content is patient focused with clear
messaging. NRG Oncology maintains an active Twitter account
(“@NRGonc”) and Facebook page, both with a focus on
engaging with the community and sharing information about
cancer clinical trials. Lastly, the study principal investigator
will conduct a study launch or kick-off session at the NRG
semiannual meeting to educate clinical investigators and
research staff on specific trial goals and requirements, as well
as to stimulate overall study awareness.

Table 1. Principal Investigator (PI) tool kit—tools for study activation phase.

a

Tasks

Responsible party

Product or placement

Study overview slide set

Protocol Development or Communications Committee •
with Study Chair review

CTSUa web page

Study landing pageb for patients

Protocol Development or Communications Committee •
with Study Chair review
•

NRG Oncology web page
CTSU web page

Patient brochure

Protocol Development or Communications Committee •
with Study Chair review
•

NRG Oncology web page
CTSU web page

Introductory letter to targeted sites with high
accrual on similar trials or potential for high
accrual

Protocol Development or Study Chair

•

Email from Study Chair

Patient-focused promotional video

Study Chair with or without patient advocate with
support from Communications Committee

•

Study chair Tweets and NRG Oncology
retweets

Study launch session

Protocol Development or Communications Committee •
with Study Chair review

NRG Oncology semiannual meeting

CTSU: Clinical Trials Support Unit.

b

Selected trials only.

Tools Used During Trial Accrual Period
A second series of tools are used during the accrual period.
Throughout the duration of the clinical trial, updates will be
given by the study principal investigator at NRG Oncology
semiannual meetings during disease-specific sessions that occur
https://cancer.jmir.org/2022/3/e38514
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every 6 months (Table 2). Study NCTN champions will provide
study updates at the different network group meetings on a
semiannual basis. The study principal investigators will submit
a “Trial in Progress” abstract to appropriate professional society
meetings including the American Society of Clinical Oncology
(ASCO) annual meetings and pertinent disease- and
JMIR Cancer 2022 | vol. 8 | iss. 3 | e38514 | p. 3
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modality-specific society meetings. The purpose of “Trial in
Progress” abstracts is to raise awareness about the trial among
other health care professionals with the goal of increasing the
number of study sites that have the trial open and available for
patients. The study principal investigator and trial leadership
(including study cochairs or subinvestigators) will also be
expected to use conference speaking opportunities to discuss
the science around the clinical trial and promote awareness

about the study design and eligible population. For trials with
industry funding available, additional investigator sessions could
be held with an industry collaborator at appropriate scientific
meetings such as the American Society of Clinical Oncology
or the American Society for Radiation Oncology. As these
investigator sessions are an additional cost, they are only
included for trials with industry funding.

Table 2. Principal investigator tool kit—tools for the accrual phase.

a

Tasks

Responsible party

Product or placement

Study updatesa

Protocol Development or PIb

NRG Oncology semiannual meeting

Trials-in-progress abstract

Study Chair or NRG Oncology publications

Conference poster at ASCOc and disease-specific society
meetings

Trial-related social media messages

Study Chair, Communications Committee, patient advo- Monthly compilation of Twitter, Facebook, and other
cates, and other stakeholders
social media platform visibility

Mention trial in education sessions Study Chair and NCTNd study champions

Relevant professional meetings

Investigator luncheon

Industry partner

Relevant professional meetings

Monitor accrual

Study Chair

Review month CTSUe reports

Selected trials only.

b

PI: principal investigator.

c

ASCO: American Society of Clinical Oncology.

d

NCTN: National Clinical Trials Network.

e

CTSU: Clinical Trials Support Unit.

A vital component of the PI tool kit is the use of social media
platforms such as Twitter. The study principal investigator with
assistance from the Communications Committee members will
be expected to engage with the scientific community through
these platforms around the clinical trial and other scientific
advances in the disease space that may be pertinent to the
ongoing clinical trial. Public communication through social
media about clinical trials is an important avenue to raise
awareness of these trials with patients, caregivers, and patient
advocacy groups, all of whom have a presence on social media
platforms. Many patient-led disease-specific advocacy groups
use social media platforms to engage with patient communities;
through collaboration with an identified patient advocate,
messaging about the importance and availability of clinical trials
may be amplified within disease-specific communities [11,12].
Importantly, every trial should identify a patient advocate to
collaborate with during the accrual period. This can be carried
out through the NRG Oncology patient advocacy committee,
which is a committee of patient advocates that works closely
with NRG Oncology on all phases of clinical trial development.
During the trial accrual period, a critical monitoring tool to be
used is monthly CTSU reports. These reports are sent to trial
principal investigators. They outline the number of study sites
that are approved to enroll study participants, as well as monthly
and overall accrual reports (Multimedia Appendix 2).

Tools to Address Barriers to Accrual
The PI tool kit includes specific tools for trials that are not
meeting accrual goals (Table 3). The first tool includes a process
for identifying barriers to patient accrual. This information can
https://cancer.jmir.org/2022/3/e38514
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be gleaned from site principal investigators during monthly
NRG Oncology disease-specific meetings. These touch points
with site principal investigators are crucial for an understanding
of major reasons for screen failure or patients declining trial
participation. After such barriers are identified, subsequent
adjustments or trial amendments can be made that address
specific issues (if required). It is crucial that the study principal
investigator maintains a high level of bidirectional
communication with site principal investigators and the disease
group such that any barriers to accrual can be identified and
addressed in a timely manner.
For trials that are not meeting accrual targets, a patient landing
page can be created that is located within the NRG Oncology
website to provide study information to health care teams and
patients in a seamless way. Other tools include site surveys to
reengage the study teams and surveys that assess the feasibility
of opening the study at other sites that are not currently open
to accrual. NCTN study champions should also be engaged
when accrual is lacking and to continue to energize the NCTN
community around trial accrual. Moreover, monthly webinars
with the study principal investigator can be used to facilitate
engagement with site principal investigators to further enhance
accrual efforts. Such engagement can be performed with
monthly protocol webinars for active study sites. Additionally,
each NCTN group has an oversight committee, which monitors
study accrual and can help address accrual issues with the study
chair of underperforming trials. Within NRG Oncology, the
POM committee reviews accrual data quarterly for all NRG
trials and connects with study principal investigators as needed
to offer support for improving accrual.
JMIR Cancer 2022 | vol. 8 | iss. 3 | e38514 | p. 4
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Table 3. Principal investigator tool kit—trials experiencing accrual barriers.

a

Tasks

Responsible party

Product or placement

Identify barriers to accrual and adapt

Study Chair or Protocol Development team

•
•

Monthly site calls or amendments
Webinar

Engage community intermediaries

Study Chair with support of disease-specific
committee and advocates

•

Targeted communication about the trial

Regular contact with institutional PIsa

Study Chair with support from Protocol Devel- •
opment
•

Monthly calls or webinars
In-person meetings

Consider study landing page (if not already
available)

Protocol Development or Communications
Committee with Study Chair review

•
•

NRG Oncology web page

Use NCTNc champions (if not already available) Study Chair with Protocol Development

•

Sponsorship of trial at other NCTN groups

Conduct site surveys

•

Assessment of feasibility of opening new
sites or reengaging existing sites

Study Chair

CTSUb web page

PIs: principal investigators.

b

CTSU: Clinical Trials Support Unit.

c

NCTN: National Clinical Trials Network.

Piloting the Study Principal Investigator Tool Kit
The NRG Oncology PI tool kit was developed in 2019, with
the idea that the tool kit would be piloted by a trial selected by
the POM committee. NRG Oncology/Alliance NRG-LU005
launched on May 28, 2019. The latter is a trial for limited-stage,
small-cell lung cancer that is testing standard chemoradiation
with or without atezolizumab. This is a phase II or III study
with a target accrual of 506 patients. Historically, clinical trials
in limited-stage, small-cell lung cancer have been difficult to
complete [13], and it was felt that the PI tool kit would be a
valuable resource to use at the outset of NRG Oncology/Alliance
NRG-LU005. The PI tool kit was used at study launch and
throughout study accrual, which was completed on June 30,
2022.

Results
NRG Oncology/Alliance NRG-LU005 has been accruing ahead
of the projected schedule since the time of study launch. This
has occurred despite the COVID-19, pandemic which began
several months after the study launched (Figure 1). As of
January 31, 2021, a total of 374 sites were approved for
enrollment; 109 (29.1%) sites have accrued at least one patient,
and 20 (5.3%) sites have accrued three patients or more. The
trial was projected to accrue 10.5 patients per month; however,
the accrual rate for the last 6 months has been 11.3 patients per
month. As of October 2, 2021, total accrual was 127% of the
projected accrual.
Compared with the rate of study accrual for Cancer and
Leukemia Group B 30610, the prior NCTN study in
limited-stage, small-cell lung cancer (activated on March 15,
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2008), NRG Oncology/Alliance NRG-LU005 accrual, which
used the PI tool kit intervention, was higher. The latter enrolled
48 patients during the first 9 months of activation, compared
with 18 patients enrolled in Cancer and Leukemia Group B
30610 during the first 9 months of activation. These 2 trials
enrolled the same patient population with very similar inclusion
criteria, including newly diagnosed, limited-stage, small-cell
lung cancer without prior treatment, with an Eastern Cooperative
Group Performance Status of 0-2 [14]. Considering the accrual
of NRG Oncology/Alliance NRG-LU005 relative to other NRG
Oncology lung cancer phase II or III trials during the same
period (June 2019 to December 2020), Figure 1 shows an accrual
greater than what was projected for NRG Oncology/Alliance
NRG-LU005, while other NRG Oncology lung cancer trials
accrued at rates less than what was projected. Additionally,
NRG Oncology/Alliance NRG-LU005 accrual was not
negatively impacted by the COVID-19 pandemic relative to
other NRG lung cancer trials, which did see reduced accrual
with the onset of the pandemic in early 2020.
In terms of operationalizing the PI tool kit, NRG Oncology
specifically assessed ongoing clinical trials for retroactive use
of study PI tool kit elements. Out of the 71 active studies, 40
(56%) are currently using at least one element of the tool kit,
with 29 studies (41%) using patient brochures, 24 (34%) with
study training slides, 26 (37%) with social media cards, 9 (13%)
with a study flyer, 6 (8%) with study newsletters, and 6 (8%)
using study-specific webinars. Given the successful adoption
of several PI tool kit elements in active studies and early
feasibility of proactive tool kit use during NRG LU-005
activation, operationalizing the PI tool kit for all new NRG
Oncology studies in development is not expected to be difficult
or costly.
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Figure 1. Accrual pace of NRG/Alliance LU005 (top panel) relative to other NRG Oncology lung cancer phase II or III trials (bottom panel).

Discussion
Principal Findings
Accrual to federally funded NCTN trials is critical to advance
cancer care and to study novel treatments. Many trials within
the NCTN portfolio fail to accrue as rapidly as projected, and
this can ultimately lead to delayed knowledge of treatment effect
or study closure as well as poor use of limited resources.
Premature closure of federally funded clinical trials ultimately
results in tax-payer dollars being used in an ineffective way. A
study of National Cancer Institute Cancer Therapy Evaluation
Program phase I-III trials between 2000 and 2007 showed that
81.5% of trials did not achieve projected accrual goals, and
37.2% failed to achieve the minimum projected accrual at study
closure [15]. This study also showed that trials that accrue the
first patient beyond 2 months from activation are significantly
less likely to achieve accrual goals [15]. Another study of NCI
cooperative group phase III trials activated from 2000 to 2007
demonstrated that the number of phase-III trials that did not
reach their projected total accrual due to insufficient enrollment
was estimated to be 22% for pediatric and adult trials combined
and 26.7% for nonpediatric trials [16]. Targeted interventions
designed to optimize accrual early, at the time of activation and
throughout the duration of the trial, are urgently needed to
answer our most pressing scientific questions in oncology.
Particularly considering the COVID-19 pandemic, with reduced
enrollment in clinical trials across the United States, methods
to help investigators overcome accrual barriers and a road map
of resources offer the potential to address trial accrual barriers
in a timely manner.
https://cancer.jmir.org/2022/3/e38514
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The NRG Oncology PI tool kit was developed to take a
multipronged approach in a style of a checklist with
accrual-enhancing activities developed and performed by both
NRG Oncology staff and the study principal investigator. The
PI tool kit uses a variety of methods to leverage optimal
engagement within the scientific and patient advocate
community. Engagement with the patient and physician
population that will participate in the trial serves as the
cornerstone of the PI tool kit, and it is expected that the study
principal investigator or physician champions have an active
and professional Twitter presence. By creating a clear road map
of activities to be performed at key time points during the study
lifetime, the study team can most optimally engage and support
trial accrual. The PI tool kit was designed to be used for any
cancer disease site and could be readily adopted by other groups
within the NCTN. The PI tool kit was piloted with NRG
Oncology/Alliance NRG-LU005, and this trial has exceeded
accrual goals despite the COVID-19 pandemic. NRG Oncology
plans to use the PI tool kit for all future phase II and III trials
that are activated. Notably, most of the tools in the tool kit are
low-cost and can be implemented with a modest degree of
infrastructure.

Comparison With Prior Work
Many of the interventions described in the tool kit use social
media platforms for awareness and engagement. The role of
social media in enhancing recruitment to clinical trials is an
active area of investigation. Social media can be leveraged to
engage with patients with cancer, including rare cancers, and
facilitate patient knowledge of and enrollment to clinical trials
JMIR Cancer 2022 | vol. 8 | iss. 3 | e38514 | p. 6
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[17]. A recent review reported that preliminary data suggest
that social media platforms can enhance patient participation
in a cost-effective manner [18]. However, there are currently
barriers to generating high-quality, evidence-based data,
specifically assessing how social media platforms impact clinical
trial accrual, primarily due the difficulties in capturing data. It
has also been suggested that social media platforms such as
Facebook and Twitter may also be tools that could improve
recruitment of minority populations to clinical trials [19]. In an
evaluation of recruitment methods to a randomized controlled
study of Spanish-speaking smokers in the United States,
Facebook was the most effective method of recruitment for
enrolling Hispanic or Latinx smokers [20].

Limitations
One important caveat to the PI tool kit is that it primarily serves
to amplify study accrual for well-designed clinical trials that
are asking important scientific questions. The success in patient
accrual seen in the first pilot trial (NRG Oncology/Alliance
NRG-LU005) is also attributed to the excitement around
immunotherapy in patients with small-cell lung cancer, given
recent data showing a survival benefit when immunotherapy is
combined with frontline chemotherapy in extensive-stage,

Higgins et al
small-cell lung cancer [21,22], which cannot be attributed to
the PI tool kit alone.
While the NRG Oncology PI tool kit focuses primarily on tools
that enhance engagement, there are certainly other tools that
could be explored to improve accrual to clinical trials. The PI
tool kit does not specifically address fundamental flaws in trial
design that could negatively impact accrual. Additionally, it
focuses on overall accrual and does not have any tools to
enhance enrollment of patients from underrepresented groups
and elderly patients, which is important for study applicability.
Future efforts for NRG Oncology include the development of
specific tools to enhance the accrual of diverse patient
populations. Lastly, the PI tool kit is in the early phase of
development, and as such, it has not been fully implemented
into all NRG Oncology trials. Implementation science
methodologies have not yet been used to fully integrate the tool
kit into all clinical trials within our organization.

Conclusions
In conclusion, the NRG Oncology PI tool kit was created to
enhance overall accrual efforts to NCI-sponsored clinical trials.
With a focus on tools that will enhance engagement across the
stakeholders in oncology care, the PI tool kit fills an unmet need
and could be widely adopted across the NCTN.
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